Balyasny Asset Management
BTAI icon

Balyasny Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Balyasny Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,300
Closed -$52.6K – 2513
2023
Q3 		$52.6K Buy
+1,300
New +$131K ﹤0.01% 2156

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's BTAI Position: Q4 2023 in Review

Balyasny Asset Management sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 1,300 shares — an estimated $52.6K sold.

Balyasny Asset Management first reported a position in BTAI in Q3 2023 and held it in 1 quarter. The position peaked at $52.6K in Q3 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Balyasny Asset Management reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 1,300 BioXcel Therapeutics shares in Q4 2023, an estimated $52.6K.
  • Balyasny Asset Management first reported a position in BioXcel Therapeutics in Q3 2023 and held it in 1 quarter.
  • Balyasny Asset Management's BioXcel Therapeutics position peaked at $52.6K in Q3 2023.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.